The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine

Main subjects:

The seroconversion rate for each antigen when EV71 is administrated with SIV

Secondary subjects:

The positive rate of antibody for each antigen when EV71 is administrated with SIV The safety for each antigen when EV71 is administrated with SIV

Inclusion criteria

• Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent.
• Participant is aged ≥ 6 month to <12 months.
• Participant without preventive inoculation of Enterovirus 71 Vaccine ,seasonal influenza vaccine vaccine and previous history of Enterovirus.
• Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures.
• Body temperature ≤ 37.0#.

Exclusion criteria

• Known allergy to any constituent of the vaccine.

• Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever.
• Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth.
• Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction.
• Known bleeding disorder.
• Receipt of the whole blood, blood plasma or immunoglobulin before the trial vaccination.
• Reported the history of acute illness had need systemic antibiotics or antiviral treatment of infections in the 7 days preceding the trial vaccination.
• An acute illness with or without fever (temperature ≥ 38.0#) in the 3 days preceding enrollment in the trial.
• Participation in any other intervention clinical trial.
• Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine.